Parkinson's Disease Treatment Market Report by Drug Class (Carbidopa/Levodopa, Dopamine Receptor Agonists, MAO Inhibitors, COMT Inhibitors, Anticholinergics, and Others), Route of Administration (Oral, Transdermal, Subcutaneous, Intestinal Infusion, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region 2025-2033

Parkinson's Disease Treatment Market Report by Drug Class (Carbidopa/Levodopa, Dopamine Receptor Agonists, MAO Inhibitors, COMT Inhibitors, Anticholinergics, and Others), Route of Administration (Oral, Transdermal, Subcutaneous, Intestinal Infusion, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region 2025-2033

Report Format: PDF+Excel | Report ID: SR112025A2792

Market Overview:

The global parkinson's disease treatment market size reached USD 5.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 8.7 Billion by 2033, exhibiting a growth rate (CAGR) of 5.14% during 2025-2033.

Report Attribute 
Key Statistics
Base Year
2024
Forecast Years
2025-2033
Historical Years
2019-2024
Market Size in 2024
USD 5.4 Billion
Market Forecast in 2033
USD 8.7 Billion
Market Growth Rate (2025-2033) 5.14%


Parkinson’s disease refers to a progressive neurological disorder caused by the degeneration of motor neurons in the brain. It is characterized by rigidity, tremors, difficulty in walking, motor impairment, depression and dementia. Some of the common treatment options for this disorder include medications, supportive therapies and surgical procedures, such as deep brain stimulation. Medications include carbidopa-levodopa medicines, dopamine agonists, monoamine oxidase B (MAO B) inhibitors, catechol O-methyltransferase (COMT) inhibitors and anticholinergics. These treatment methods are highly effective in managing the symptoms of Parkinson’s disease and providing comfort to the patient in case of a seizure.

Global Parkinson's Disease Treatment Market Trends and Drivers:

The increasing prevalence of Parkinson’s disease, and the rising geriatric population across the globe, which is more susceptible to neurodegenerative ailments, represent as the key factors driving the growth of the market. Furthermore, the increasing awareness among the masses regarding the available treatment alternatives is also stimulating the market growth. In line with this, COMT inhibitors are gaining immense traction among healthcare providers and patients. They are administered along with co-therapeutic agents and carbidopa-levodopa therapy for maximum efficiency. Additionally, various innovations in the disease treatment methods, such as the development of neurostimulation tools, gene therapy and neural transplantation procedures, are acting as other growth-inducing factors. These procedures aid in prolonged action of unremitting dopaminergic stimulation medicines and facilitate slowing down the disease progression, which, in turn, is creating a positive outlook for the market. Other factors, including significant improvements in the healthcare infrastructure, along with extensive research and development (R&D) activities, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global parkinson's disease treatment market report, along with forecasts at the global, regional and country levels from 2025-2033. Our report has categorized the market based on drug class, route of administration and distribution channel.

Breakup by Drug Class:

  • Carbidopa/Levodopa
  • Dopamine Receptor Agonists
  • MAO Inhibitors
  • COMT Inhibitors
  • Anticholinergics
  • Others
     

Breakup by Route of Administration:

  • Oral
  • Transdermal
  • Subcutaneous
  • Intestinal Infusion
  • Others
     

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
     

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
     

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being AbbVie Inc., Acadia Pharmaceuticals Inc., Boehringer Ingelheim International GmbH (C. H. Boehringer Sohn AG & Co. KG), F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, H. Lundbeck A/S, Merck & Co. Inc., Mylan N.V., Novartis AG, Orion Corporation, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries and Wockhardt Ltd.

Report Coverage:

Report Features Details
Base Year of the Analysis 2024
Historical Period 2019-2024
Forecast Period 2025-2033
Units Billion USD
Segment Coverage Drug Class, Route of Administration, Distribution Channel, Region
Region Covered Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered AbbVie Inc., Acadia Pharmaceuticals Inc., Boehringer Ingelheim International GmbH (C. H. Boehringer Sohn AG & Co. KG), F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, H. Lundbeck A/S, Merck & Co. Inc., Mylan N.V., Novartis AG, Orion Corporation, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries and Wockhardt Ltd.
Customization Scope 10% Free Customization
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


Key Questions Answered in This Report:

  • How has the global parkinson’s disease treatment market performed so far and how will it perform in the coming years?
  • What are the key regional markets?
  • What has been the impact of COVID-19 on the global parkinson’s disease treatment market?
  • What is the breakup of the market based on the drug class?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global parkinson’s disease treatment market and who are the key players?
  • What is the degree of competition in the industry? 

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Parkinson's Disease Treatment Market Report by Drug Class (Carbidopa/Levodopa, Dopamine Receptor Agonists, MAO Inhibitors, COMT Inhibitors, Anticholinergics, and Others), Route of Administration (Oral, Transdermal, Subcutaneous, Intestinal Infusion, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region 2025-2033
Purchase Options New Year Sale
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials